{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,7]],"date-time":"2026-04-07T21:29:33Z","timestamp":1775597373441,"version":"3.50.1"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2021,11,3]],"date-time":"2021-11-03T00:00:00Z","timestamp":1635897600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2021,11,3]],"date-time":"2021-11-03T00:00:00Z","timestamp":1635897600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Invest New Drugs"],"published-print":{"date-parts":[[2022,4]]},"DOI":"10.1007\/s10637-021-01172-9","type":"journal-article","created":{"date-parts":[[2021,11,3]],"date-time":"2021-11-03T09:03:12Z","timestamp":1635930192000},"page":"453-460","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Rh-endostatin combined with chemotherapy in patients with advanced or recurrent mucosal melanoma: retrospective analysis of real-world data"],"prefix":"10.1007","volume":"40","author":[{"given":"Xiaowei","family":"Zhang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Feng","family":"Jin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shiyu","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jun","family":"Cao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yanchun","family":"Meng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yu","family":"Xu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"family":"ChunmengWang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yong","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Huijuan","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yunyi","family":"Kong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xin","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhiguo","family":"Luo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,11,3]]},"reference":[{"issue":"3","key":"1172_CR1","first-page":"193","volume":"181","author":"A Barth","year":"1995","unstructured":"Barth A, Wanek LA, Morton DL (1995) Prognostic factors in 1,521 melanoma patients with distant metastases. J Am Coll Surg 181(3):193\u2013201","journal-title":"J Am Coll Surg"},{"issue":"4","key":"1172_CR2","doi-asserted-by":"publisher","first-page":"868","DOI":"10.1093\/annonc\/mdw694","volume":"28","author":"B Lian","year":"2017","unstructured":"Lian B, Cui C-L, Zhou L, Song X, Zhang X-S, Wu D, Si L, Chi Z-H, Sheng X-N, Mao L-L, Wang X, Tang B-X, Yan X-Q, Kong Y, Dai J, Li SM, Bai X, Zheng N, Balch C-M, Guo J (2017) The natural history and patterns of metastases from mucosal melanoma: an analysis of 706 prospectively-followed patients. Annals of oncology: official J European Soc Med Oncol 28(4):868\u2013873. https:\/\/doi.org\/10.1093\/annonc\/mdw694","journal-title":"Annals of oncology: official J European Soc Med Oncol"},{"issue":"2","key":"1172_CR3","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1200\/JCO.2016.67.9258","volume":"35","author":"SP D'Angelo","year":"2017","unstructured":"D\u2019Angelo SP, Larkin J, Sosman JA, Lebb\u00e9 C, Brady B, Neyns B, Schmidt H, Hassel JC, Hodi FS, Lorigan P, Savage KJ, Miller WH Jr, Mohr P, Marquez-Rodas I, Charles J, Kaatz M, Sznol M, Weber JS, Shoushtari AN, Ruisi M, Wolchok JD (2017) Efficacy and Safety of Nivolumab Alone or in Combination With Ipilimumab in Patients With Mucosal Melanoma: A Pooled Analysis. Journal of clinical oncology:\u00a0Official J European Soc Med Oncol 35(2):226\u2013235. https:\/\/doi.org\/10.1200\/JCO.2016.67.9258","journal-title":"Journal of clinical oncology:\u00a0Official J European Soc Med Oncol"},{"issue":"4","key":"1172_CR4","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1111\/jop.12358","volume":"45","author":"J Lyu","year":"2016","unstructured":"Lyu J, Wu Y, Li C, Wang R, Song RG, Guo W (2016) Mutation scanning of BRAF, NRAS, KIT, and GNAQ\/GNA11 in oral mucosal melanoma: a study of 57 cases. Journal of oral pathology and medicine: official publication of the International Association of Oral Pathologists and the American Academy of Oral Pathology 45(4):295\u2013301. https:\/\/doi.org\/10.1111\/jop.12358","journal-title":"Journal of oral pathology and medicine: official publication of the International Association of Oral Pathologists and the American Academy of Oral Pathology"},{"issue":"7","key":"1172_CR5","doi-asserted-by":"publisher","first-page":"848","DOI":"10.1634\/theoncologist.2015-0522","volume":"21","author":"D Kuk","year":"2016","unstructured":"Kuk D, Shoushtari AN, Barker CA, Panageas KS, Munhoz RR, Momtaz P, Ariyan CE, Brady MS, Coit DG, Bogatch K, Callahan MK, Wolchok JD, Carvajal RD, Postow MA (2016) Prognosis of Mucosal, Uveal, Acral, Nonacral Cutaneous, and Unknown Primary Melanoma from the Time of First Metastasis. Oncologist 21(7):848\u2013854. https:\/\/doi.org\/10.1634\/theoncologist.2015-0522","journal-title":"Oncologist"},{"key":"1172_CR6","doi-asserted-by":"publisher","unstructured":"McLaughlin CC, Wu XC, Jemal A, Martin HJ, Roche LM, Chen VW (2005) Incidence of noncutaneous melanomas in the U.S.\u00a0Cancer\u00a0103(5):1000\u20131007. https:\/\/doi.org\/10.1002\/cncr.20866","DOI":"10.1002\/cncr.20866"},{"key":"1172_CR7","doi-asserted-by":"publisher","unstructured":"Chi Z, Li S, Sheng X, Si L, Cui C, Han M, Guo, J (2011) Clinical presentation, histology, and prognoses of malignant melanoma in ethnic Chinese: a study of 522 consecutive cases.\u00a0BMC cancer\u00a011(85). https:\/\/doi.org\/10.1186\/1471-2407-11-85","DOI":"10.1186\/1471-2407-11-85"},{"issue":"2","key":"1172_CR8","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1016\/s0092-8674(00)81848-6","volume":"88","author":"MS O'Reilly","year":"1997","unstructured":"O\u2019Reilly MS, Boehm T, Shing Y, Fukai N, Vasios G, Lane WS, Flynn E, Birkhead JR, Olsen BR, Folkman J (1997) Endostatin: an endogenous inhibitor of angiogenesis and tumor growth. Cell 88(2):277\u2013285. https:\/\/doi.org\/10.1016\/s0092-8674(00)81848-6","journal-title":"Cell"},{"issue":"24","key":"1172_CR9","first-page":"6251","volume":"59","author":"SS Yoon","year":"1999","unstructured":"Yoon SS, Eto H, Lin CM, Nakamura H, Pawlik TM, Song SU, Tanabe KK (1999) Mouse endostatin inhibits the formation of lung and liver metastases. Can Res 59(24):6251\u20136256","journal-title":"Can Res"},{"issue":"19","key":"1172_CR10","first-page":"5410","volume":"60","author":"YM Kim","year":"2000","unstructured":"Kim YM, Jang JW, Lee OH, Yeon J, Choi EY, Kim KW, Lee ST, Kwon YG (2000) Endostatin inhibits endothelial and tumor cellular invasion by blocking the activation and catalytic activity of matrix metalloproteinase. Can Res 60(19):5410\u20135413","journal-title":"Can Res"},{"issue":"6658","key":"1172_CR11","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1038\/37126","volume":"390","author":"T Boehm","year":"1997","unstructured":"Boehm T, Folkman J, Browder T, O\u2019Reilly MS (1997) Antiangiogenic therapy of experimental cancer does not induce acquired drug resistance. Nature 390(6658):404\u2013407. https:\/\/doi.org\/10.1038\/37126","journal-title":"Nature"},{"issue":"1","key":"1172_CR12","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1158\/0008-5472.can-03-1829","volume":"64","author":"L Mendoza","year":"2004","unstructured":"Mendoza L, Valc\u00e1rcel M, Carrascal T, Egilegor E, Salado C, Sim BK, Vidal-Vanaclocha F (2004) Inhibition of cytokine-induced microvascular arrest of tumor cells by recombinant endostatin prevents experimental hepatic melanoma metastasis. Can Res 64(1):304\u2013310. https:\/\/doi.org\/10.1158\/0008-5472.can-03-1829","journal-title":"Can Res"},{"key":"1172_CR13","doi-asserted-by":"publisher","unstructured":"Han B, Xiu Q, Wang H, Shen J, Gu A, Luo Y, Bai C, Guo S, Liu W, Zhuang Z, Zhang Y, Zhao Y, Jiang L, Zhou J, Jin X (2011) A multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy of paclitaxel-carboplatin alone or with endostar for advanced non-small cell lung cancer.\u00a0Journal of thoracic oncology: official publication of the International Association for the Study of Lung Cancer. 6(6):1104\u20131109.https:\/\/doi.org\/10.1097\/JTO.0b013e3182166b6b","DOI":"10.1097\/JTO.0b013e3182166b6b"},{"issue":"4","key":"1172_CR14","doi-asserted-by":"publisher","first-page":"1027","DOI":"10.1007\/s00280-011-1576-1","volume":"68","author":"Z-T Zhou","year":"2011","unstructured":"Zhou Z-T, Zhou F-X, Wei Q, Zou L-Y, Qin B-F, Peng X-S (2011) Phase II study of cisplatin\/etoposide and endostar for extensive-stage small-cell lung cancer. Cancer Chemother Pharmacol 68(4):1027\u20131032. https:\/\/doi.org\/10.1007\/s00280-011-1576-1","journal-title":"Cancer Chemother Pharmacol"},{"issue":"1","key":"1172_CR15","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1097\/JTO.0000000000000343","volume":"10","author":"S Lu","year":"2015","unstructured":"Lu S, Li L, Luo Y, Zhang L, Wu G, Chen Z, Huang C, Guo S, Zhang Y, Song X, Yu Y, Zhou C, Li W, Liao M, Li B, Xu L, Chen P, Hu C, Hu C (2015) A multicenter, open-label, randomized phase II controlled study of rh-endostatin (Endostar) in combination with chemotherapy in previously untreated extensive-stage small-cell lung cancer. Journal of thoracic oncology: official publication of the International Association for the Study of Lung Cancer 10(1):206\u2013211. https:\/\/doi.org\/10.1097\/JTO.0000000000000343","journal-title":"Journal of thoracic oncology: official publication of the International Association for the Study of Lung Cancer"},{"issue":"Supplement","key":"1172_CR16","doi-asserted-by":"publisher","first-page":"S1148","DOI":"10.4103\/0973-1482.204880","volume":"14","author":"H Yang","year":"2018","unstructured":"Yang H, Sui Y, Guo X, Tan X, Li Y, Wang M (2018) Endostar continuous intravenous infusion combined with S-1 and oxaliplatin chemotherapy could be effective in treating liver metastasis from gastric cancer. J Cancer Res Ther 14(Supplement):S1148\u2013S1151. https:\/\/doi.org\/10.4103\/0973-1482.204880","journal-title":"J Cancer Res Ther"},{"issue":"24","key":"1172_CR17","first-page":"4299","volume":"124","author":"J-F Zhou","year":"2011","unstructured":"Zhou J-F, Bai C-M, Wang Y-Z, Li X-Y, Cheng Y-J, Chen S-C (2011) Endostar combined with chemotherapy for treatment of metastatic colorectal and gastric cancer: a pilot study. Chin Med J 124(24):4299\u20134303","journal-title":"Chin Med J"},{"issue":"2","key":"1172_CR18","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1007\/s12253-011-9447-y","volume":"18","author":"Y Jia","year":"2012","unstructured":"Jia Y, Liu M, Huang W, Wang Z, He Y, Wu J, Ren S, Ju Y, Geng R, Li Z (2012) Recombinant human endostatin endostar inhibits tumor growth and metastasis in a mouse xenograft model of colon cancer. Pathology oncology research: POR 18(2):315\u2013323. https:\/\/doi.org\/10.1007\/s12253-011-9447-y","journal-title":"Pathology oncology research: POR"},{"issue":"3","key":"1172_CR19","doi-asserted-by":"publisher","first-page":"1841","DOI":"10.7314\/apjcp.2013.14.3.1841","volume":"14","author":"A Su","year":"2013","unstructured":"Su A, Zhang J, Pan Z-H, Zhou Q-M, Lv X (2013) Salvage therapy of gemcitabine plus endostar significantly improves progression-free survival (PFS) with platinum-resistant recurrent epithelial ovarian cancer. Asian Pacific journal of cancer prevention: APJCP 14(3):1841\u20131846. https:\/\/doi.org\/10.7314\/apjcp.2013.14.3.1841","journal-title":"Asian Pacific journal of cancer prevention: APJCP"},{"issue":"2","key":"1172_CR20","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1016\/j.tranon.2018.01.002","volume":"11","author":"T Jin","year":"2018","unstructured":"Jin T, Jiang F, Jin Q-F, Piao Y-F, Chen X-Z (2018) Endostar Combined with Gemcitabine and Cisplatin Chemotherapy for Patients with Metastatic Nasopharyngeal Carcinoma: an Update. Translational oncology 11(2):286\u2013291. https:\/\/doi.org\/10.1016\/j.tranon.2018.01.002","journal-title":"Translational oncology"},{"key":"1172_CR21","doi-asserted-by":"publisher","unstructured":"Guan Y, Li A, Xiao W, Liu S, Chen B, Lu T, Zhao C, Han F (2015) The efficacy and safety of Endostar combined with chemoradiotherapy for patients with advanced, locally recurrent nasopharyngeal carcinoma.\u00a0Oncotarget\u00a06(32):33926\u201333934. https:\/\/doi.org\/10.18632\/oncotarget.5271","DOI":"10.18632\/oncotarget.5271"},{"issue":"1","key":"1172_CR22","doi-asserted-by":"publisher","DOI":"10.1016\/j.currproblcancer.2019.06.007","volume":"44","author":"Y Li","year":"2020","unstructured":"Li Y, Tian Y, Jin F, Wu W, Long J, Ouyang J, Zhou Y (2020) A phase II multicenter randomized controlled trial to compare standard chemoradiation with or without recombinant human endostatin injection (Endostar) therapy for the treatment of locally advanced nasopharyngeal carcinoma: Long-term outcomes update. Curr Probl Cancer 44(1):100492. https:\/\/doi.org\/10.1016\/j.currproblcancer.2019.06.007","journal-title":"Curr Probl Cancer"},{"issue":"7","key":"1172_CR23","doi-asserted-by":"publisher","first-page":"1456","DOI":"10.1038\/mt.2013.79","volume":"21","author":"C Cui","year":"2013","unstructured":"Cui C, Mao L, Chi Z, Si L, Sheng X, Kong Y, Li S, Lian B, Gu K, Tao M, Song X, Lin T, Ren X, Qin S, Guo J (2013) A phase II, randomized, double-blind, placebo-controlled multicenter trial of Endostar in patients with metastatic melanoma. Molecular therapy: the journal of the American Society of Gene Therapy 21(7):1456\u20131463. https:\/\/doi.org\/10.1038\/mt.2013.79","journal-title":"Molecular therapy: the journal of the American Society of Gene Therapy"},{"issue":"3","key":"1172_CR24","doi-asserted-by":"publisher","first-page":"345","DOI":"10.6004\/jnccn.2012.0034","volume":"10","author":"RD Carvajal","year":"2012","unstructured":"Carvajal RD, Spencer SA, Lydiatt W (2012) Mucosal melanoma: a clinically and biologically unique disease entity. Journal of the National Comprehensive Cancer Network: JNCCN 10(3):345\u2013356. https:\/\/doi.org\/10.6004\/jnccn.2012.0034","journal-title":"Journal of the National Comprehensive Cancer Network: JNCCN"},{"issue":"1","key":"1172_CR25","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1200\/JCO.2000.18.1.158","volume":"18","author":"MR Middleton","year":"2000","unstructured":"Middleton MR, Grob JJ, Aaronson N, Fierlbeck G, Tilgen W, Seiter S, Gore M, Aamdal S, Cebon J, Coates A, Dreno B, Henz M, Schadendorf D, Kapp A, Weiss J, Fraass U, Statkevich P, Muller M, Thatcher N (2000) Randomized phase III study of temozolomide versus dacarbazine in the treatment of patients with advanced metastatic malignant melanoma. Journal of clinical oncology: official journal of the American Society of Clinical Oncology 18(1):158\u2013166. https:\/\/doi.org\/10.1200\/JCO.2000.18.1.158","journal-title":"Journal of clinical oncology: official journal of the American Society of Clinical Oncology"},{"key":"1172_CR26","doi-asserted-by":"publisher","unstructured":"Eggermont AM, Kirkwood JM (2004) Re-evaluating the role of dacarbazine in metastatic melanoma: what have we learned in 30 years.\u00a0European journal of cancer (Oxford, England:1990)\u00a040(12):1825\u20131836. https:\/\/doi.org\/10.1016\/j.ejca.2004.04.030","DOI":"10.1016\/j.ejca.2004.04.030"},{"issue":"5","key":"1172_CR27","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1007\/s11912-012-0244-x","volume":"14","author":"MA Postow","year":"2012","unstructured":"Postow MA, Hamid O, Carvajal RD (2012) Mucosal melanoma: pathogenesis, clinical behavior, and management. Curr Oncol Rep 14(5):441\u2013448. https:\/\/doi.org\/10.1007\/s11912-012-0244-x","journal-title":"Curr Oncol Rep"},{"issue":"4","key":"1172_CR28","doi-asserted-by":"publisher","first-page":"898","DOI":"10.1111\/1759-7714.13333","volume":"11","author":"H-L Ma","year":"2020","unstructured":"Ma H-L, Hui Z-G, Peng F, Zhao LJ, Li D-M, Xu Y-J, Bao Y, Xu L-M, Zhai Y-R, Hu X, Wang J, Kong Y, Wang L-H, Chen M (2020) Different administration routes of recombinant human endostatin combined with concurrent chemoradiotherapy might lead to different efficacy and safety profile in unresectable stage III non-small cell lung cancer: Updated follow-up results from two phase II trials. Thoracic cancer 11(4):898\u2013906. https:\/\/doi.org\/10.1111\/1759-7714.13333","journal-title":"Thoracic cancer"},{"issue":"7","key":"1172_CR29","first-page":"4350","volume":"35","author":"CL Cui","year":"2015","unstructured":"Cui CL, Lu S, Chi ZH, Sheng XN, Mao LL, Wang X, Lian B, Yan XQ, Guo J (2015) Preliminary results of a phase II trial with continuous intravenous infusion of rh-endostatin in combination with dacarbazine as the first-line therapy for metastatic acral melanoma. Anticancer Res 35(7):4350\u20134351","journal-title":"Anticancer Res"},{"issue":"6","key":"1172_CR30","doi-asserted-by":"publisher","first-page":"828","DOI":"10.1016\/j.tranon.2019.02.007","volume":"12","author":"L Si","year":"2019","unstructured":"Si L, Zhang X-S, Shu Y-Q, Pan H-M, Wu D, Liu JW, Lou F, Mao L-L, Wang X, Wen XZ, Gu YH, Zhu LJ, Lan SJ, Cai X, Diede SJ, Zhou Y, Ge J, Li JF, Wu HY, Guo J (2019) A Phase Ib Study of Pembrolizumab as Second-Line Therapy for Chinese Patients With Advanced or Metastatic Melanoma (KEYNOTE-151). Translational oncology 12(6):828\u2013835. https:\/\/doi.org\/10.1016\/j.tranon.2019.02.007","journal-title":"Translational oncology"},{"issue":"16","key":"1172_CR31","doi-asserted-by":"publisher","first-page":"4250","DOI":"10.1158\/1078-0432.CCR-19-3922","volume":"26","author":"B Tang","year":"2020","unstructured":"Tang B, Chi Z, Chen Y, Liu X, Wu D, Chen J, Song X, Wang W, Dong L, Song H, Wu H, Feng H, Yao S, Qin S, Zhang X, Guo J (2020) Safety, Efficacy, and Biomarker Analysis of Toripalimab in Previously Treated Advanced Melanoma: Results of the POLARIS-01 Multicenter Phase II Trial. Clinical cancer research: an official journal of the American Association for Cancer Research 26(16):4250\u20134259. https:\/\/doi.org\/10.1158\/1078-0432.CCR-19-3922","journal-title":"Clinical cancer research: an official journal of the American Association for Cancer Research"},{"issue":"32","key":"1172_CR32","doi-asserted-by":"publisher","first-page":"2987","DOI":"10.1200\/JCO.19.00210","volume":"37","author":"X Sheng","year":"2019","unstructured":"Sheng X, Yan X, Chi Z, Si L, Cui C, Tang B, Li S, Mao L, Lian B, Wang X, Bai X, Zhou L, Kong Y, Dai J, Wang K, Tang X, Zhou H, Wu H, Feng H, Yao S, Guo J (2019) Axitinib in Combination With Toripalimab, a Humanized Immunoglobulin G4 Monoclonal Antibody Against Programmed Cell Death-1, in Patients With Metastatic Mucosal Melanoma: An Open-Label Phase IB Trial. Journal of clinical oncology: official journal of the American Society of Clinical Oncology 37(32):2987\u20132999. https:\/\/doi.org\/10.1200\/JCO.19.00210","journal-title":"Journal of clinical oncology: official journal of the American Society of Clinical Oncology"},{"key":"1172_CR33","doi-asserted-by":"crossref","unstructured":"Si L, Sheng XN, Mao LL, Li CL, Wang X, Bai X, Qi Z, Chi ZH, Cui CL, Lian B, Tang BX, Yan XQ, Zhou L, Li SM, Duan R (2020) A phase II study of vorolanib (CM082) in combination with toripalimab (JS001) in patients with advanced mucosal melanoma. J Clin Oncol\u00a038(15_suppl):10040\u201310040","DOI":"10.1200\/JCO.2020.38.15_suppl.10040"},{"key":"1172_CR34","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/j.ijsu.2018.01.002","volume":"50","author":"J-Y Ma","year":"2018","unstructured":"Ma J-Y, Liu Q (2018) Clinicopathological and prognostic significance of lymphocyte to monocyte ratio in patients with gastric cancer: A meta-analysis. International journal of surgery (London, England) 50:67\u201371. https:\/\/doi.org\/10.1016\/j.ijsu.2018.01.002","journal-title":"International journal of surgery (London, England)"},{"key":"1172_CR35","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1186\/s12935-018-0698-5","volume":"18","author":"Y Mao","year":"2018","unstructured":"Mao Y, Chen D, Duan S, Zhao Y, Wu C, Zhu F, Chen C, Chen Y (2018) Prognostic impact of pretreatment lymphocyte-to-monocyte ratio in advanced epithelial cancers: a meta-analysis. Cancer Cell Int 18:201. https:\/\/doi.org\/10.1186\/s12935-018-0698-5","journal-title":"Cancer Cell Int"},{"issue":"10","key":"1172_CR36","doi-asserted-by":"publisher","first-page":"971","DOI":"10.1016\/j.ctrv.2015.10.003","volume":"41","author":"TF Nishijima","year":"2015","unstructured":"Nishijima TF, Muss HB, Shachar SS, Tamura K, Takamatsu Y (2015) Prognostic value of lymphocyte-to-monocyte ratio in patients with solid tumors: A systematic review and meta-analysis. Cancer Treat Rev 41(10):971\u2013978. https:\/\/doi.org\/10.1016\/j.ctrv.2015.10.003","journal-title":"Cancer Treat Rev"},{"issue":"5","key":"1172_CR37","doi-asserted-by":"publisher","first-page":"510","DOI":"10.1097\/CMR.0000000000000584","volume":"29","author":"D Lacono","year":"2019","unstructured":"Lacono D, Basile D, Gerratana L, Vitale MG, Pelizzari G, Cinausero M, Poletto E, Puglisi F, Fasola G, Minisini AM (2019) Prognostic role of disease extent and lymphocyte-monocyte ratio in advanced melanoma. Melanoma Res 29(5):510\u2013515. https:\/\/doi.org\/10.1097\/CMR.0000000000000584","journal-title":"Melanoma Res"},{"issue":"1","key":"1172_CR38","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1097\/CMR.0000000000000290","volume":"27","author":"Leontovich AA, Dronca RS, Nevala WK, Thompson M, Kottschade LA, Ivanov LV, Markovic SN, Melanoma Study Group of the Mayo Clinic Cancer Center","year":"2017","unstructured":"Leontovich AA, Dronca RS, Nevala WK, Thompson M, Kottschade LA, Ivanov LV, Markovic SN, Melanoma Study Group of the Mayo Clinic Cancer Center (2017) Effect of the lymphocyte-to-monocyte ratio on the clinical outcome of chemotherapy administration in advanced melanoma patients. Melanoma Res 27(1):32\u201342. https:\/\/doi.org\/10.1097\/CMR.0000000000000290","journal-title":"Melanoma Res"},{"issue":"5","key":"1172_CR39","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1684\/ejd.2018.3381","volume":"28","author":"T Minowa","year":"2018","unstructured":"Minowa T, Kato J, Hida T, Horimoto K, Sato S, Sawada M, Uhara H (2018) Prognostic role of platelet to lymphocyte and lymphocyte to monocyte ratios in advanced melanoma treated with anti-programmed death-1. European journal of dermatology: EJD 28(5):705\u2013707. https:\/\/doi.org\/10.1684\/ejd.2018.3381","journal-title":"European journal of dermatology: EJD"},{"key":"1172_CR40","doi-asserted-by":"publisher","first-page":"995","DOI":"10.3389\/fonc.2019.00995","volume":"9","author":"Y Wang","year":"2019","unstructured":"Wang Y, Zhang H, Yang Y, Zhang T, Ma X (2019) Prognostic Value of Peripheral Inflammatory Markers in Preoperative Mucosal Melanoma: A Multicenter Retrospective Study. Front Oncol 9:995. https:\/\/doi.org\/10.3389\/fonc.2019.00995","journal-title":"Front Oncol"},{"issue":"12","key":"1172_CR41","doi-asserted-by":"publisher","first-page":"1564","DOI":"10.1038\/bjc.2017.125","volume":"116","author":"M Amit","year":"2017","unstructured":"Amit M, Tam S, Abdelmeguid AS, Roberts DB, Takahashi Y, Raza SM, Su SY, Kupferman ME, DeMonte F, Hanna EY (2017) Mutation status among patients with sinonasal mucosal melanoma and its impact on survival. Br J Cancer 116(12):1564\u20131571. https:\/\/doi.org\/10.1038\/bjc.2017.125","journal-title":"Br J Cancer"}],"container-title":["Investigational New Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10637-021-01172-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10637-021-01172-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10637-021-01172-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,11]],"date-time":"2023-03-11T04:40:59Z","timestamp":1678509659000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10637-021-01172-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11,3]]},"references-count":41,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2022,4]]}},"alternative-id":["1172"],"URL":"https:\/\/doi.org\/10.1007\/s10637-021-01172-9","relation":{},"ISSN":["0167-6997","1573-0646"],"issn-type":[{"value":"0167-6997","type":"print"},{"value":"1573-0646","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,11,3]]},"assertion":[{"value":"23 June 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 August 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 November 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"All authors approved the final manuscript for publication.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interests"}}]}}